Moreover, when the procoagulant activity of these MPs was analyzed, the authors reported that it increased particularly in PV versus ET or PMF (88% versus 73.2% and 68.3%, respectively; p = 0.002), as well as in JAK2 V617F-positive (78.1%) versus JAK2 V617F-negative (66.7%) MPNs (p = 0.007), particularly in those subjects with an elevated allele burden (p = 0.001). The gene discussed is JAK2; the disease is essential thrombocythemia.